July 1, 2020 -- Lysogene has inked a research agreement with Yeda Research and Development, the commercial arm of the Weizmann Institute of Science, for novel gene therapy.
Through the collaboration, Lysogene and Anthony Futerman, PhD, of the Weizmann Institute will work to develop a novel adeno-associated virus (AAV) gene therapy approach for neuronopathic Gaucher disease, Parkinson's disease, and other diseases associated with mutations of the GBA1 gene.
Under the terms of the agreement, Lysogene will provide expertise in AAV vector design and production, while Futerman's lab will provide glucocerebrosidase variants with enhanced biological properties and conduct proof-of-concept biological studies. Subsequently, Lysogene will have the option to license the program.
Copyright © 2020 scienceboard.net